NANJING KING-FRIEND BIOCHEMICAL PHARMACEUTICAL CO.,LTD. Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. Share Price
Equities
603707
CNE100002WP3
Pharmaceuticals
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13.24 CNY | +0.46% |
|
+8.70% | -11.73% |
| 01-16 | King-Friend Biochemical Pharmaceutical's Unit Gets US FDA Nod to Market Oxaliplatin Injection | MT |
| 01-11 | NKFPharma Gets Certificate to Register Voriconazole for Injection | MT |
| Sales 2023 | 3.93B 543M 43.45B | Sales 2024 * | 5.23B 722M 57.79B | Capitalization | 21.33B 2.94B 236B |
|---|---|---|---|---|---|
| Net income 2023 | -189M -26.08M -2.09B | Net income 2024 * | 1.34B 184M 14.77B | EV / Sales 2023 | 6.15 x |
| Net cash position 2023 * | - 0 0 | Net cash position 2024 * | - 0 0 | EV / Sales 2024 * | 4.08 x |
| P/E ratio 2023 |
-125
x | P/E ratio 2024 * |
16
x | Employees | 1,396 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 26.7% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.46% | ||
| 1 week | +8.70% | ||
| Current month | +18.11% | ||
| 1 month | +17.58% | ||
| 3 months | -1.27% | ||
| 6 months | +11.82% | ||
| Current year | -11.73% |
1 week
12.15
13.44
1 month
10.7513.44
Current year
10.7515.38
1 year
10.7516.40
3 years
10.7534.60
5 years
10.1335.52
10 years
2.8035.52
| Managers | Title | Age | Since |
|---|---|---|---|
Yong Qun Tang
CEO | Chief Executive Officer | 49 | 31/12/03 |
Xiao Jie Qian
DFI | Director of Finance/CFO | 44 | 31/12/10 |
Xi Wei Huang
BRD | Director/Board Member | 54 | 31/03/11 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Xi Wei Huang
BRD | Director/Board Member | 54 | 31/03/11 |
Ping Shi
BRD | Director/Board Member | 62 | 15/05/19 |
Yong Qun Tang
CEO | Chief Executive Officer | 49 | 31/12/03 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.49% | 2 M€ | -16.59% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 13.24 | +0.46% | 7,840,400 |
| 25/04/24 | 13.18 | +2.81% | 11,665,470 |
| 24/04/24 | 12.82 | 0.00% | 5,736,652 |
| 23/04/24 | 12.82 | +0.31% | 9,597,075 |
| 22/04/24 | 12.78 | +4.93% | 10,988,290 |
End-of-day quote Shanghai S.E., April 25, 2024
More quotes
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. is a China-based company principally engaged in the research and development, production and sales of heparin-related products. The Company's main products include standard heparin raw materials, low molecular weight heparin raw materials and their preparations, such as heparin sodium raw materials, heparin sodium, enoxaparin sodium injection, dalteparin sodium injection and Naqu Heparin Calcium Injection. The Company mainly exports its products to the United States and European countries.
Sector
Pharmaceuticals
Calendar
26/04/2024
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
D
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
13.24
CNY
Average target price
20.18
CNY
Spread / Average Target
+52.45%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -11.73% | 2.94B | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- 603707 Stock
